25

30

What is claimed is:

- A method of haplotype determination in an individual for diagnostic or prognostic purposes, comprising determining a nucleotide from said nucleic acid which corresponds to the nucleotide occupying more than one Seq-40 polymorphic sites selected from the group consisting of the polymorphic sites at positions:
 - (1) 601 and 2106,
 - (2) 194 and 2106,
 - (3) 194 and 601,
- 10 (4) 1038 and 2106,
 - (5) 601, 1038 and 2106,
 - (6) 601,1038 and 2185,
 - (7) 194, 1038 and 2106,
 - (8) 194, 601 and 1038,
- 15 (9) 194, 1038 and 2185,
 - (10) 601, 1038 and 2359,
 - (11) 194, 601 and 2106,
 - (12) 194, 601 and 1038,
 - (13) 601, 2106 and 2359,
- 20 (14) 601, 2106 and 2185,
 - (15) 601, 1038 and 2106,
 - (16) 601, 1038 and 2359,
 - (17) 194, 601 and 2106,
 - (18) 601, 1038, 2106 and 2185,
 - (19) 194, 601, 1038 and 2106,
 - (20) 194, 1038, 2106 and 2185,
 - (21) 194, 601, 1038 and 2185,
 - (22) 601, 1038, 2185 and 2359,
 - (23) 601, 1038, 2106 and 2359,
 - (24) 194, 1038, 2185 and 2359 and
 - (25) 194, 601, 1038 and 2359

of SEQ ID NO: 1 on a single chromosome.

2. The method of claim 1, wherein the determining comprises determining the identity of the nucleotide at position 601 of SEQ ID NO:1 or a fragment thereof and determining the identity of the nucleotide at position 2106 of SEQ ID NO:1 or a fragment thereof.

5

3. The method of claim 1, wherein the determining comprises determining the identity of the nucleotide at position 194 of SEQ ID NO:1 or a fragment thereof and determining the identity of the nucleotide at position 2106 of SEQ ID NO:1 or a fragment thereof.

10

4. The method of claim 1, wherein the determining comprises determining the identity of the nucleotide at position 194 of SEQ ID NO:1 or a fragment thereof and determining the identity of the nucleotide at position 601 of SEQ ID NO:1 or a fragment thereof.

15

5. The method of claim 1, wherein the determining comprises determining the identity of the nucleotide at position 1038 of SEQ ID NO:1 or a fragment thereof and determining the identity of the nucleotide at position 2106 of SEQ ID NO:1 or a fragment thereof.

20

25

- 6. The method of claim 1, wherein the determining comprises determining the identity of the nucleotide at position 601 of SEQ ID NO:1 or a fragment thereof, determining the identity of the nucleotide at position 1038 of SEQ ID NO:1 or a fragment thereof and determining the identity of the nucleotide at position 2106 of SEQ ID NO:1 or a fragment thereof.
- 7. The method of claim 1, wherein the determining comprises determining the identity of the nucleotide at position 601 of SEQ ID NO:1 or a fragment thereof, determining the identity of the nucleotide at position 1038 of SEQ ID NO:1 or a fragment thereof and determining the identity of the nucleotide at position 2185 of SEQ ID NO:1 or a fragment thereof.

10

15

- 8. The method of claim 1, wherein the determining comprises determining the identity of the nucleotide at position 194 of SEQ ID NO:1 or a fragment thereof, determining the identity of the nucleotide at position 1038 of SEQ ID NO:1 or a fragment thereof and determining the identity of the nucleotide at position 2106 of SEQ ID NO:1 or a fragment thereof.
- 9. The method of claim 1, wherein the determining comprises determining the identity of the nucleotide at position 194 of SEQ ID NO:1 or a fragment thereof, determining the identity of the nucleotide at position 601 of SEQ ID NO:1 or a fragment thereof and determining the identity of the nucleotide at position 1038 of SEQ ID NO:1 or a fragment thereof.
- 10. The method of claim 1, wherein the determining comprises determining the identity of the nucleotide at position 194 of SEQ ID NO:1 or a fragment thereof, determining the identity of the nucleotide at position 1038 of SEQ ID NO:1 or a fragment thereof and determining the identity of the nucleotide at position 2185 of SEQ ID NO:1 or a fragment thereof.
- 11. The method of claim 1, wherein the determining comprises determining the identity of the nucleotide at position 601 of SEQ ID NO:1 or a fragment thereof, determining the identity of the nucleotide at position 1038 of SEQ ID NO:1 or a fragment thereof and determining the identity of the nucleotide at position 2359 of SEQ ID NO:1 or a fragment thereof.
- 12. The method of claim 1, wherein the determining comprises determining the identity of the nucleotide at position 194 of SEQ ID NO:1 or a fragment thereof, determining the identity of the nucleotide at position 601 of SEQ ID NO:1 or a fragment thereof and determining the identity of the nucleotide at position 2106 of SEQ ID NO:1 or a fragment thereof.
 - 13. The method of claim 1, wherein the determining comprises determining the identity of the nucleotide at position 194 of SEQ ID NO:1 or a fragment thereof, determining the identity of the nucleotide at position 601 of SEQ ID NO:1 or a

fragment thereof and determining the identity of the nucleotide at position 1038 of SEQ ID NO:1 or a fragment thereof.

- 14. The method of claim 1, wherein the determining comprises determining the identity of the nucleotide at position 601 of SEQ ID NO:1 or a fragment thereof, determining the identity of the nucleotide at position 2106 of SEQ ID NO:1 or a fragment thereof and determining the identity of the nucleotide at position 2359 of SEQ ID NO:1 or a fragment thereof.
- 15. The method of claim 1, wherein the determining comprises determining the identity of the nucleotide at position 601 of SEQ ID NO:1 or a fragment thereof, determining the identity of the nucleotide at position 2106 of SEQ ID NO:1 or a fragment thereof and determining the identity of the nucleotide at position 2185 of SEQ ID NO:1 or a fragment thereof.

15

20

25

30

- 16. The method of claim 1, wherein the determining comprises determining the identity of the nucleotide at position 601 of SEQ ID NO:1 or a fragment thereof, determining the identity of the nucleotide at position 1038 of SEQ ID NO:1 or a fragment thereof and determining the identity of the nucleotide at position 2106 of SEQ ID NO:1 or a fragment thereof.
- 17. The method of claim 1, wherein the determining comprises determining the identity of the nucleotide at position 601 of SEQ ID NO:1 or a fragment thereof, determining the identity of the nucleotide at position 1038 of SEQ ID NO:1 or a fragment thereof and determining the identity of the nucleotide at position 2359 of SEQ ID NO:1 or a fragment thereof.
- 18. The method of claim 1, wherein the determining comprises determining the identity of the nucleotide at position 194 of SEQ ID NO:1 or a fragment thereof, determining the identity of the nucleotide at position 601 of SEQ ID NO:1 or a fragment thereof and determining the identity of the nucleotide at position 2106 of SEQ ID NO:1 or a fragment thereof.

10

- 19. The method of claim 1, wherein the determining comprises determining the identity of the nucleotide at position 601 of SEQ ID NO:1 or a fragment thereof, determining the identity of the nucleotide at position 1038 of SEQ ID NO:1 or a fragment thereof, determining the identity of the nucleotide at position 2106 of SEQ ID NO:1 or a fragment thereof and determining the identity of the nucleotide at position 2185 of SEQ ID NO:1 or a fragment thereof.
- 20. The method of claim 1, wherein the determining comprises determining the identity of the nucleotide at position 194 of SEQ ID NO:1 or a fragment thereof, determining the identity of the nucleotide at position 601 of SEQ ID NO:1 or a fragment thereof, determining the identity of the nucleotide at position 1038 of SEQ ID NO:1 or a fragment thereof and determining the identity of the nucleotide at position 2106 of SEQ ID NO:1 or a fragment thereof.
- 15 21. The method of claim 1, wherein the determining comprises determining the identity of the nucleotide at position 194 of SEQ ID NO:1 or a fragment thereof, determining the identity of the nucleotide at position 1038 of SEQ ID NO:1 or a fragment thereof, determining the identity of the nucleotide at position 2106 of SEQ ID NO:1 or a fragment thereof and determining the identity of the nucleotide at position 2185 of SEQ ID NO:1 or a fragment thereof.
 - 22. The method of claim 1, wherein the determining comprises determining the identity of the nucleotide at position 194 of SEQ ID NO:1 or a fragment thereof, determining the identity of the nucleotide at position 601 of SEQ ID NO:1 or a fragment thereof, determining the identity of the nucleotide at position 1038 of SEQ ID NO:1 or a fragment thereof and determining the identity of the nucleotide at position 2185 of SEQ ID NO:1 or a fragment thereof.
- 23. The method of claim 1, wherein the determining comprises determining the identity of the nucleotide at position 601 of SEQ ID NO:1 or a fragment thereof, determining the identity of the nucleotide at position 1038 of SEQ ID NO:1 or a fragment thereof, determining the identity of the nucleotide at position 2185 of

SEQ ID NO:1 or a fragment thereof and determining the identity of the nucleotide at position 2359 of SEQ ID NO:1 or a fragment thereof.

24. The method of claim 1, wherein the determining comprises determining the identity of the nucleotide at position 601 of SEQ ID NO:1 or a fragment thereof, determining the identity of the nucleotide at position 1038 of SEQ ID NO:1 or a fragment thereof, determining the identity of the nucleotide at position 2106 of SEQ ID NO:1 or a fragment thereof and determining the identity of the nucleotide at position 2359 of SEQ ID NO:1 or a fragment thereof.

10

15

20

5

- 25. The method of claim 1, wherein the determining comprises determining the identity of the nucleotide at position 194 of SEQ ID NO:1 or a fragment thereof, determining the identity of the nucleotide at position 1038 of SEQ ID NO:1 or a fragment thereof, determining the identity of the nucleotide at position 2185 of SEQ ID NO:1 or a fragment thereof and determining the identity of the nucleotide at position 2359 of SEQ ID NO:1 or a fragment thereof.
- 26. The method of claim 1, wherein the determining comprises determining the identity of the nucleotide at position 194 of SEQ ID NO:1 or a fragment thereof, determining the identity of the nucleotide at position 601 of SEQ ID NO:1 or a fragment thereof, determining the identity of the nucleotide at position 1038 of SEQ ID NO:1 or a fragment thereof and determining the identity of the nucleotide at position 2359 of SEQ ID NO:1 or a fragment thereof.
- 27. The method of claim 1, wherein the determining comprises amplification of the DNA.
 - 28. The method of claim 1 wherein the determining comprises multiple PCR amplification of specific alleles.

30

29. A method of evaluating the propensity of a patient to develop schizophrenia comprising:

determining a nucleotide from a nucleic acid obtained from said patient which corresponds to the nucleotide occupying one or more Seq-40 polymorphic sites at positions

- 1) 601 and 1038,
- 5 (2) 194 and 1038,
 - (3) 601 and 2106,
 - (4) 194 and 2106,
 - (5) 194 and 601,
 - (6) 1038 and 2106,
- 10 (7) 601, 1038 and 2106,
 - (8) 601,1038 and 2185,
 - (9) 194, 1038 and 2106,
 - (10) 194, 601 and 1038,
 - (11) 194, 1038 and 2185,
- 15 (12) 601, 1038 and 2359,
 - (13) 194, 601 and 2106,
 - (14) 194, 601 and 1038,
 - (15) 601, 2106 and 2359,
 - (16) 601, 2106 and 2185,
- 20 (17) 601, 1038 and 2106,
 - (18) 601, 1038 and 2359,
 - (19) 194, 601 and 2106,
 - (20) 601, 1038, 2106 and 2185,
 - (21) 194, 601, 1038 and 2106,
- 25 (22) 194, 1038, 2106 and 2185,
 - (23) 194, 601, 1038 and 2185,
 - (24) 601, 1038, 2185 and 2359,
 - (25) 601, 1038, 2106 and 2359,
 - (26) 194, 1038, 2185 and 2359 and
- 30 (27) 194, 601, 1038 and 2359

of SEQ ID NO: 1 on a single chromosome, and evaluating whether the patient has a propensity to develop schizophrenia.

10

15

- 30. The method of claim 29, wherein the evaluation step comprises determining that the patient has a propensity to develop schizophrenia if the identity of the nucleotide at position 601 of SEQ ID NO:1 or a fragment thereof is a G and if the identity of the nucleotide at position 1038 of SEQ ID NO:1 or a fragment thereof is a C.
- 31. The method of claim 29, wherein the evaluation step comprises determining that the patient has a propensity to develop schizophrenia if the identity of the nucleotide at position 194 of SEQ ID NO:1 or a fragment thereof is an A and if the identity of the nucleotide at position 1038 of SEQ ID NO:1 or a fragment thereof is a C.
- 32. The method of claim 29, wherein the evaluation step comprises determining that the patient has a propensity to develop schizophrenia if the identity of the nucleotide at position 601 of SEQ ID NO:1 or a fragment thereof is a G and if the identity of the nucleotide at position 2106 of SEQ ID NO:1 or a fragment thereof is a G.
- 33. The method of claim 29, wherein the evaluation step comprises determining that
 the patient has a propensity to develop schizophrenia if the identity of the
 nucleotide at position 194 of SEQ ID NO:1 or a fragment thereof is an A and if
 the identity of the nucleotide at position 2106 of SEQ ID NO:1 or a fragment
 thereof is a G.
- 25 34. The method of claim 29, wherein the evaluation step comprises determining that the patient has a propensity to develop schizophrenia if the identity of the nucleotide at position 194 of SEQ ID NO:1 or a fragment thereof is a G and if the identity of the nucleotide at position 601 of SEQ ID NO:1 or a fragment thereof is a G.

30

35. The method of claim 29, wherein the evaluation step comprises determining that the patient has less of a propensity to develop schizophrenia if the identity of the nucleotide at position 1038 of SEQ ID NO:1 or a fragment thereof is a G and if

the identity of the nucleotide at position 2106 of SEQ ID NO:1 or a fragment thereof is an A.

36. The method of claim 29, wherein the evaluation step comprises determining that the patient has less of a propensity to develop schizophrenia if the identity of the nucleotide at position 601 of SEQ ID NO:1 or a fragment thereof is a G, if the identity of the nucleotide at position 1038 of SEQ ID NO:1 or a fragment thereof is a C and if the identity of the nucleotide at position 2106 of SEQ ID NO:1 or a fragment thereof is a G.

10

15

20

- 37. The method of claim 29, wherein the evaluation step comprises determining that the patient has a propensity to develop schizophrenia if the identity of the nucleotide at position 601 of SEQ ID NO:1 or a fragment thereof is a G, if the identity of the nucleotide at position 1038 of SEQ ID NO:1 or a fragment thereof is a C and if the identity of the nucleotide at position 2185 of SEQ ID NO:1 or a fragment thereof is a G.
- 38. The method of claim 29, wherein the evaluation step comprises determining that the patient has less of a propensity to develop schizophrenia if the identity of the nucleotide at position 194 of SEQ ID NO:1 or a fragment thereof is an A, if the identity of the nucleotide at position 1038 of SEQ ID NO:1 or a fragment thereof is a C and if the identity of the nucleotide at position 2106 of SEQ ID NO:1 or a fragment thereof is a G.
- 25 39. The method of claim 29, wherein the evaluation step comprises determining that the patient has a propensity to develop schizophrenia if the identity of the nucleotide at position 194 of SEQ ID NO:1 or a fragment thereof is a A, if the identity of the nucleotide at position 601 of SEQ ID NO:1 or a fragment thereof is a G and if the identity of the nucleotide at position 1038 of SEQ ID NO:1 or a fragment thereof is a C
 - 40. The method of claim 29, wherein the evaluation step comprises determining that the patient has a propensity to develop schizophrenia if the identity of the

nucleotide at position 194 of SEQ ID NO:1 or a fragment thereof is an A, if the identity of the nucleotide at position 1038 of SEQ ID NO:1 or a fragment thereof is a C or G and if the identity of the nucleotide at position 2185 of SEQ ID NO:1 or a fragment thereof is a G or A.

5

10

15

- 41. The method of claim 29, wherein the evaluation step comprises determining that the patient has a propensity to develop schizophrenia if the identity of the nucleotide at position 601 of SEQ ID NO:1 or a fragment thereof is a G, if the identity of the nucleotide at position 1038 of SEQ ID NO:1 or a fragment thereof is a C and if the identity of the nucleotide at position 2359 of SEQ ID NO:1 or a fragment thereof is a G.
- 42. The method of claim 29, wherein the evaluation step comprises determining that the patient has a propensity to develop schizophrenia if the identity of the nucleotide at position 194 of SEQ ID NO:1 or a fragment thereof is an A, if the identity of the nucleotide at position 601 of SEQ ID NO:1 or a fragment thereof is a G and if the identity of the nucleotide at position 2106 of SEQ ID NO:1 or a fragment thereof is an A.
- 43. The method of claim 29, wherein the evaluation step comprises determining that the patient has a propensity to develop schizophrenia if the identity of the nucleotide at position 194 of SEQ ID NO:1 or a fragment thereof is a G, if the identity of the nucleotide at position 601 of SEQ ID NO:1 or a fragment thereof is a G and if the identity of the nucleotide at position 1038 of SEQ ID NO:1 or a fragment thereof is a C.
 - 44. The method of claim 29, wherein the evaluation step comprises determining that the patient has a propensity to develop schizophrenia if the identity of the nucleotide at position 601 of SEQ ID NO:1 or a fragment thereof is a G, if the identity of the nucleotide at position 2106 of SEQ ID NO:1 or a fragment thereof is a G and if the identity of the nucleotide at position 2359 of SEQ ID NO:1 or a fragment thereof is a G.

10

- 45. The method of claim 29, wherein the evaluation step comprises determining that the patient has a propensity to develop schizophrenia if the identity of the nucleotide at position 601 of SEQ ID NO:1 or a fragment thereof is a G, if the identity of the nucleotide at position 2106 of SEQ ID NO:1 or a fragment thereof is a G and if the identity of the nucleotide at position 2185 of SEQ ID NO:1 or a fragment thereof is a G.
- 46. The method of claim 29, wherein the evaluation step comprises determining that the patient has a propensity to develop schizophrenia if the identity of the nucleotide at position 601 of SEQ ID NO:1 or a fragment thereof is a G, if the identity of the nucleotide at position 1038 of SEQ ID NO:1 or a fragment thereof is an A and if the identity of the nucleotide at position 2106 of SEQ ID NO:1 or a fragment thereof is an A.
- 15 47. The method of claim 29, wherein the evaluation step comprises determining that the patient has a propensity to develop schizophrenia if the identity of the nucleotide at position 601 of SEQ ID NO:1 or a fragment thereof is a G, if the identity of the nucleotide at position 1038 of SEQ ID NO:1 or a fragment thereof is a C and if the identity of the nucleotide at position 2359 of SEQ ID NO:1 or a fragment thereof is a T.
 - 48. The method of claim 29, wherein the evaluation step comprises determining that the patient has less of a propensity to develop schizophrenia if the identity of the nucleotide at position 194 of SEQ ID NO:1 or a fragment thereof is an A, if the identity of the nucleotide at position 601 of SEQ ID NO:1 or a fragment thereof is a G and if the identity of the nucleotide at position 2106 of SEQ ID NO:1 or a fragment thereof is a G.
- 49. The method of claim 29, wherein the evaluation step comprises determining that
 the patient has a propensity to develop schizophrenia if the identity of the
 nucleotide at position 601 of SEQ ID NO:1 or a fragment thereof is a G, if the
 identity of the nucleotide at position 1038 of SEQ ID NO:1 or a fragment thereof
 is a C, if the identity of the nucleotide at position 2106 of SEQ ID NO:1 or a

10

15

30

fragment thereof is a G if the identity of the nucleotide at position 2185 of SEQ ID NO:1 or a fragment thereof is a G.

- 50. The method of claim 29, wherein the evaluation step comprises determining that the patient has less of a propensity to develop schizophrenia if the identity of the nucleotide at position 194 of SEQ ID NO:1 or a fragment thereof is an A, if the identity of the nucleotide at position 601 of SEQ ID NO:1 or a fragment thereof is a G, if the identity of the nucleotide at position 1038 of SEQ ID NO:1 or a fragment thereof is a C and if the identity of the nucleotide at position 2106 of SEQ ID NO:1 or a fragment thereof is a G.
- 51. The method of claim 29, wherein the evaluation step comprises determining that the patient has a propensity to develop schizophrenia if the identity of the nucleotide at position 194 of SEQ ID NO:1 or a fragment thereof is an A, if the identity of the nucleotide at position 1038 of SEQ ID NO:1 or a fragment thereof is a C, if the identity of the nucleotide at position 2106 of SEQ ID NO:1 or a fragment thereof is a G and if the identity of the nucleotide at position 2185 of SEQ ID NO:1 or a fragment thereof is a G.
- 52. The method of claim 29, wherein the evaluation step comprises determining that the patient has a propensity to develop schizophrenia if the identity of the nucleotide at position 194 of SEQ ID NO:1 or a fragment thereof is an A, if the identity of the nucleotide at position 601 of SEQ ID NO:1 or a fragment thereof is a G, if the identity of the nucleotide at position 1038 of SEQ ID NO:1 or a fragment thereof is a C and if the identity of the nucleotide at position 2185 of SEQ ID NO:1 or a fragment thereof is a G.
 - 53. The method of claim 29, wherein the evaluation step comprises determining that the patient has a propensity to develop schizophrenia if the identity of the nucleotide at position 601 of SEQ ID NO:1 or a fragment thereof is a G, if the identity of the nucleotide at position 1038 of SEQ ID NO:1 or a fragment thereof is a C, if the identity of the nucleotide at position 2185 of SEQ ID NO:1 or a

10

15

fragment thereof is a G and if the identity of the nucleotide at position 2359 of SEQ ID NO:1 or a fragment thereof is a T.

- 54. The method of claim 29, wherein the evaluation step comprises determining that the patient has a propensity to develop schizophrenia if the identity of the nucleotide at position 601 of SEQ ID NO:1 or a fragment thereof is a G, if the identity of the nucleotide at position 1038 of SEQ ID NO:1 or a fragment thereof is a C, if the identity of the nucleotide at position 2106 of SEQ ID NO:1 or a fragment thereof is a G and if the identity of the nucleotide at position 2359 of SEQ ID NO:1 or a fragment thereof is a T or G.
- 55. The method of claim 29, wherein the evaluation step comprises determining that the patient has a propensity to develop schizophrenia if the identity of the nucleotide at position 194 of SEQ ID NO:1 or a fragment thereof is an A, if the identity of the nucleotide at position 1038 of SEQ ID NO:1 or a fragment thereof is a C, if the identity of the nucleotide at position 2185 of SEQ ID NO:1 or a fragment thereof is a G and if the identity of the nucleotide at position 2359 of SEQ ID NO:1 or a fragment thereof is a T.
- 56. The method of claim 29, wherein the evaluation step comprises determining that the patient has a propensity to develop schizophrenia if the identity of the nucleotide at position 194 of SEQ ID NO:1 or a fragment thereof is an A, if the identity of the nucleotide at position 601 of SEQ ID NO:1 or a fragment thereof is a G, if the identity of the nucleotide at position 1038 of SEQ ID NO:1 or a fragment thereof is a C and if the identity of the nucleotide at position 2359 of SEQ ID NO:1 or a fragment thereof is a G.